Theratechnologies Inc. (Theratechnologies, or the Company (on a
consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies, is pleased to announce the addition of two
new senior resources to support the growth and development of its
commercial and pipeline assets. Effective today, Theratechnologies
is pleased to welcome Mr. John Leasure as Global Commercial Officer
and Mr. Peter Kowal as Vice President, HIV-U.S. Commercial
Operations.
“Both John and Peter bring important
capabilities that are needed to bring Theratechnologies to our next
stage of growth. I am very pleased that we were able to attract
such talented and experienced individuals with expertise across
HIV, endocrinology, and oncology. I look forward to their
contributions toward the growth of our commercial assets and the
development of our pipeline. On behalf of the entire team at
Theratechnologies, I want to extend the warmest welcome to our new
colleagues,” said Paul Lévesque, President and Chief Executive
Officer, Theratechnologies.
Mr. Leasure spent 30 years at Pfizer in the
United States and Canada where he held increasingly senior
functions in the Anti-infectives, Inflammation Immunology and
Oncology businesses. Most recently, Mr. Leasure led Pfizer’s
Oncology business unit in Canada where, under his leadership, the
business experienced unprecedented growth and launched over 10 new
products. In his new function, Mr. Leasure will oversee
Theratechnologies’ HIV-U.S. business and will also develop global
capabilities in Marketing, Pricing & Reimbursement, Analytics,
Manufacturing, Sourcing and Drug Development as well as New Project
Planning. These functional areas will support both the Company’s
U.S. and European operations and serve to enhance the Company’s
global business efficiencies. Mr. Leasure holds a B.A. in
Management from Gettysburg College. He will report directly to the
President and Chief Executive Officer of Theratechnologies, Mr.
Paul Lévesque, and will be based in the United States.
Mr. Kowal has spent 23 years in various
pharmaceutical sales and marketing positions, specializing in the
areas of HIV and endocrinology. Most recently, he was U.S. Head,
Sales, Marketing, Strategy and Operations at Merck KGaA-EMD Serono,
Inc. Mr. Kowal brings significant expertise to the Company’s
HIV-U.S. business and will oversee sales, access and reimbursement
efforts, while working very closely with marketing to ensure an
optimal deployment of resources. Mr. Kowal holds a Master of
Education from Temple University and a B.Sc. in Biology from Ithaca
College. Mr. Kowal will report to John Leasure and will be based in
the United States.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies addressing unmet medical needs. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and
forward-looking information, or, collectively, forward-looking
statements, within the meaning of applicable securities laws, that
are based on our management’s beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", “would”, "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the growth of Theratechnologies
and the development of its pipeline.
Forward-looking statements are based upon a
number of assumptions and include, but are not limited to, the
following: sales of our products in the United States will increase
over time, our products will not be subject to recalls, no unknown
side effects will be discovered from the long-term use of our
products, our products will continue to be reimbursed by
third-party payors, pre-clinical in vivo results obtained with
TH1902 will be replicated in humans during the Phase 1 trial, we
will be able to determine the maximum tolerated dose of TH1902 in
the Phase 1, treatment with TH1902 will be efficacious and safe in
various types of cancer, we will be able to enroll patients to
complete our Phase 1 trial using TH1902, we will meet our announced
timelines, including those related to the beginning of our Phase 3
trial using tesamorelin for NASH and we will have the funds
necessary to carry out our business plan.
Forward-looking statements are subject to a
variety of risks and uncertainties, many of which are beyond our
control that could cause our actual results to differ materially
from those that are disclosed in or implied by the forward-looking
statements contained in this press release. These risks and
uncertainties include, among others, the risk that the current
Covid-19 pandemic forces us to adversely amend our previously
announced timelines because, among other factors, of safety
measures implemented in the United States and in Europe, employees’
illness and shortage of products or materials, that the sales of
our products decrease over time, that we are subject to product
recalls, that adverse safety issues are discovered from the
long-term use of our products, that we are found to be in violation
of laws and regulation governing the commercialization of products
resulting in the payment of fines or other penalties, that our
intellectual property on our products is challenged and found to be
invalid, that we are unable to replicate pre-clinical in vivo
results obtained with TH1902 when administered into humans, that we
are unable to enroll patients for our proposed clinical trials and
that we do not have the funds necessary to complete our planned
clinical trial.
We refer potential investors to the "Risk
Factors" section of our annual information form dated February 24,
2021 available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov as an exhibit to our report on Form 40-F dated February
25, 2021 under Theratechnologies’ public filings for additional
risks regarding the conduct of our business and Theratechnologies.
The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
For media inquiries:Denis BoucherVice President, Communications
and Corporate
Affairs514-336-7800communications@theratech.com
For investor inquiries:Leah GibsonSenior Director, Investor
Relations617-356-1009ir@theratech.com
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Sep 2023 to Sep 2024